In confirmation, immunoblotting revealed a dose dependent reduction in expression of CSC makers (Sox2, Oct4, Nanog and ALDH1A1) in the ART-treated tumors compared to the untreated tumor (Figure 6B). Here, ALDH1A1 is linked to neoplasm.